

## Special Issue

# Recent Advances in Large-Cell Lymphomas

### Message from the Guest Editor

Lymphoma is one of the most common malignant tumors, with an increasing number of cases year by year. Lymphomas are classified into more than 100 subtypes in the current WHO classification. This year, the WHO established criteria for the classification of hematolymphoid tumors based on recent advances in the clinicopathological and genomic/genetic findings. At the same time, the Clinical Advisory Committee also published the International Consensus Classification (ICC). These two classifications are similar in view of the progress to date, but there are several differences in the nomenclature of types and definitions of disease subtypes. In the future, these two classifications will be utilized in parallel, recognizing their differences and the developing hematopathology. This Special Issue focuses on recent advances in lymphomas, particularly those composed of large cells, irrespective of lineage. We seek expert review articles as well as research articles on recent advances in large-cell lymphomas.

---

### Guest Editor

Prof. Dr. Shuji Momose

Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama 350-8550, Japan

---

### Deadline for manuscript submissions

closed (30 September 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/146671](https://mdpi.com/si/146671)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)